IRON
MCID: IRN002
MIFTS: 57

Iron Metabolism Disease (IRON)

Categories: Blood diseases, Metabolic diseases, Respiratory diseases

Aliases & Classifications for Iron Metabolism Disease

MalaCards integrated aliases for Iron Metabolism Disease:

Name: Iron Metabolism Disease 12 15
Iron Deficiency 74 54 71 32
Iron Metabolism Disorders 44 71
Iron Disorder 12 54
Disorder of Iron Metabolism 12
Iron 42

Classifications:



External Ids:

Disease Ontology 12 DOID:2351
ICD9CM 34 275.0
MeSH 44 D019189
SNOMED-CT 67 30913008
ICD10 32 E61.1 E83.1
UMLS 71 C0012715 C0240066

Summaries for Iron Metabolism Disease

MedlinePlus : 42 Iron is a mineral that our bodies need for many functions. For example, iron is part of hemoglobin, a protein which carries oxygen from our lungs throughout our bodies. It helps our muscles store and use oxygen. Iron is also part of many other proteins and enzymes. Your body needs the right amount of iron. If you have too little iron, you may develop iron deficiency anemia. Causes of low iron levels include blood loss, poor diet, or an inability to absorb enough iron from foods. People at higher risk of having too little iron are young children and women who are pregnant or have periods. Too much iron can damage your body. Taking too many iron supplements can cause iron poisoning. Some people have an inherited disease called hemochromatosis. It causes too much iron to build up in the body. Centers for Disease Control and Prevention

MalaCards based summary : Iron Metabolism Disease, also known as iron deficiency, is related to neurodegeneration with brain iron accumulation 3 and hemochromatosis, type 2b. An important gene associated with Iron Metabolism Disease is HFE (Homeostatic Iron Regulator), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Glucose / Energy Metabolism. The drugs Iron protein succinylate and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and bone marrow, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 74 Iron deficiency, or sideropenia, is the state in which a body lacks enough iron to supply its needs.... more...

Related Diseases for Iron Metabolism Disease

Diseases related to Iron Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2006)
# Related Disease Score Top Affiliating Genes
1 neurodegeneration with brain iron accumulation 3 32.1 SLC11A2 IREB2 FTL CP ACO1
2 hemochromatosis, type 2b 31.8 HAMP FTL
3 congenital dyserythropoietic anemia 31.8 TFRC HFE HAMP EPO
4 hemochromatosis, type 5 31.8 TFR2 HJV HFE FTL
5 hemochromatosis, type 2a 31.7 HJV HAMP
6 friedreich ataxia 31.7 TFRC IREB2 HFE ACO1
7 anemia, congenital dyserythropoietic, type ia 31.4 TFRC HJV HAMP EPO
8 hemochromatosis, type 3 31.2 TFRC TFR2 SLC40A1 SLC11A2 HJV HFE
9 atransferrinemia 31.2 TFRC TFR2 TF SLC40A1 SLC11A2 HJV
10 neurodegeneration with brain iron accumulation 31.1 TFRC TFR2 SLC40A1 SLC11A2 IREB2 HFE
11 restless legs syndrome 31.0 TFRC SLC11A2 IREB2 HAMP FTL EPO
12 thalassemia minor 30.9 HBB EPO
13 hemochromatosis, type 4 30.8 TFRC TFR2 SLC40A1 SLC11A2 HJV HFE
14 hemosiderosis 30.7 TFR2 TF SLC40A1 SLC11A2 HJV HFE
15 arthropathy 30.6 HJV HFE HAMP CRP
16 hyperferritinemia with or without cataract 30.5 TFR2 TF SLC40A1 SLC11A2 IREB2 HJV
17 porphyria cutanea tarda 30.5 TFRC TFR2 TF SLC40A1 HJV HFE
18 iron-refractory iron deficiency anemia 30.4 HJV EPO
19 polycythemia 30.3 TFRC HBB HAMP EPO
20 sickle cell disease 30.2 TFRC HBB G6PD EPO
21 nutritional deficiency disease 30.2 TFRC TF HJV HAMP EPO CRP
22 neutropenia 30.1 TFRC EPO CRP CP
23 eales disease 30.1 TF CP
24 hemolytic anemia 30.1 TFRC TF HBB G6PD EPO
25 acute erythroid leukemia 30.1 HBB EPO
26 sickle cell anemia 30.0 HBB G6PD EPO CRP
27 alpha-1-antitrypsin deficiency 29.9 IREB2 HFE HAMP
28 anemia of prematurity 29.9 HAMP EPO
29 protoporphyria, erythropoietic, 1 29.9 TFRC IREB2 ACO1
30 acquired polycythemia 29.8 HAMP EPO
31 macrophage activation syndrome 29.8 FTL CRP
32 aceruloplasminemia 29.8 TFRC TFR2 SLC40A1 SLC11A2 IREB2 HJV
33 asphyxia neonatorum 29.8 EPO CRP
34 beta-thalassemia major 29.8 HFE HBB
35 analbuminemia 29.7 TF EPO CRP
36 plasmodium falciparum malaria 29.7 HBB G6PD CRP
37 respiratory failure 29.7 TF G6PD EPO CRP
38 splenic sequestration 29.7 HBB EPO
39 sideroblastic anemia 29.7 TFR2 SLC40A1 IREB2 HFE HAMP ACO1
40 rare hereditary hemochromatosis 29.6 TFR2 TF SLC40A1 HJV HFE HAMP
41 hypochromic microcytic anemia 29.6 TFRC TF SLC11A2 IREB2 HJV HBB
42 cutaneous porphyria 29.6 HFE HAMP
43 hereditary spherocytosis 29.6 TFRC HFE HBB G6PD
44 anemia, sideroblastic, 1 29.6 TFRC TFR2 SLC40A1 SLC11A2 IREB2 HJV
45 alpha-thalassemia 29.6 TFRC HFE HBB HAMP G6PD EPO
46 folic acid deficiency anemia 29.5 TFRC HAMP EPO CRP
47 rh isoimmunization 29.5 G6PD EPO
48 hemoglobinopathy 29.4 TFRC TFR2 TF HJV HFE HBB
49 viral hepatitis 29.4 HFE G6PD CRP CP
50 extrapulmonary tuberculosis 29.4 SLC11A1 HAMP CRP

Comorbidity relations with Iron Metabolism Disease via Phenotypic Disease Network (PDN):


Deficiency Anemia Pulmonary Hemosiderosis

Graphical network of the top 20 diseases related to Iron Metabolism Disease:



Diseases related to Iron Metabolism Disease

Symptoms & Phenotypes for Iron Metabolism Disease

MGI Mouse Phenotypes related to Iron Metabolism Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 ACO1 CP CRP CYBRD1 EPO FTL
2 hematopoietic system MP:0005397 10.21 CP EPO FTL G6PD HEPH HFE
3 cardiovascular system MP:0005385 10.18 CP CRP CYBRD1 EPO G6PD HEPH
4 immune system MP:0005387 10.1 CP CRP EPO FTL HEPH HFE
5 integument MP:0010771 9.81 EPO HEPH HJV IREB2 SLC11A1 SLC11A2
6 liver/biliary system MP:0005370 9.73 CP CYBRD1 EPO FTL HEPH HFE
7 nervous system MP:0003631 9.36 CP FTL G6PD HEPH HFE HJV

Drugs & Therapeutics for Iron Metabolism Disease

Drugs for Iron Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 457)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Iron protein succinylate Approved, Investigational Phase 4 250705-13-6
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Ferrous gluconate Approved Phase 4 299-29-6
4
Ferrous fumarate Approved Phase 4 141-01-5
5
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
6
Ferrous succinate Approved Phase 4 10030-90-7
7
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
8
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
9
Deferiprone Approved Phase 4 30652-11-0 2972
10
Halofantrine Approved Phase 4 69756-53-2 37393
11
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
12
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
13
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
14
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
15
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
16
Copper Approved, Investigational Phase 4 7440-50-8 27099
17
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
18
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
19
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
20
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
21
Ferric maltol Approved Phase 4 33725-54-1
22
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381 214348
23
tannic acid Approved Phase 4 1401-55-4
24
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
26
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
27
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
28
Taurine Approved, Nutraceutical Phase 4 107-35-7 1123
29
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
30
Choline Approved, Nutraceutical Phase 4 62-49-7 305
31
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
32
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
33
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
34
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
35
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
36
Cobalamin Experimental Phase 4 13408-78-1 6857388
37
Trichostatin A Experimental Phase 4 58880-19-6
38
Enclomiphene Investigational Phase 4 15690-57-0
39 Calamus Phase 4
40 ferric gluconate Phase 4
41 Vitamin B Complex Phase 4
42 Vitamin B9 Phase 4
43 Folate Phase 4
44 Antirheumatic Agents Phase 4
45 Vitamin B 12 Phase 4
46 Vitamin B12 Phase 4
47 Amebicides Phase 4
48 Iron Chelating Agents Phase 4
49 Zinc Supplement Phase 4
50 Anti-Allergic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1356)
# Name Status NCT ID Phase Drugs
1 The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children Unknown status NCT01418898 Phase 4
2 Does Intraoperative Intravenous Iron Sucrose Enhance Postoperative Oxygenation Profile in Total Arthroplasty Surgery? Unknown status NCT02544828 Phase 4 Iron Sucrose 200mg;placebo
3 The Effect of Intra Venus Ferric Carboxymaltose Preoperative on Hemoglobin and Blood Transfusion Post Cardiac Surgery Unknown status NCT02939794 Phase 4 Ferinject;Placebo
4 Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial Unknown status NCT03830034 Phase 4 Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
5 Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension Unknown status NCT01288651 Phase 4 Ferricarboxymaltose
6 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
7 Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance In Non Anemic Premenopausal Women With Low Ferritin Levels Unknown status NCT01374776 Phase 4 Double blind, randomized, placebo controlled inter
8 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
9 A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting Unknown status NCT01950247 Phase 4 Injectafer;SOC
10 a Randomized Control Trial to Assess the Effect of Early vs Routine Iron Supplementation on Iron Store and Growth in Term Small for Gestational Age and Appropriate for Gestational Age Infants at 1 Year Unknown status NCT03171324 Phase 4 Iron Supplement
11 Effectiveness of Iron Supplementation in the Second Year of Life for Prevention of Iron Deficiency Unknown status NCT00479102 Phase 4 Ferripel-3 - iron polysaccharide complex for prevention
12 Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy? Unknown status NCT03347513 Phase 4 triple attack therapy;Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
13 A Randomized, Double-blind, Multi-center Clinical Trial Prospectively Evaluating Iron Protein Succinylate Oral Solution in Treating Patients With Chronic Heart Failure and Iron Deficiency Unknown status NCT03344523 Phase 4 Iron protein succinylate oral solution
14 Effectiveness of Weekly and Daily Iron Supplementation for the Prevention of Iron-deficiency Anemia in Infants. Impact on Genomic Stability Unknown status NCT03359447 Phase 4 Weekly Ferrous Sulfate;Daily Ferrous Sulfate
15 Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations. Unknown status NCT00248716 Phase 4 Ferrous gluconate and iron polysaccharide complex
16 Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial. Unknown status NCT02242188 Phase 4 Iron
17 The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
18 Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe Unknown status NCT02487719 Phase 4 Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia
19 Bovine Lactoferrin Versus Ferrous Sulphate In The Treatment Of Iron Deficiency Anemia During Pregnancy: A Randomized Controlled Trial Unknown status NCT03202615 Phase 4 F (ferrous sulphate)
20 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
21 Combination With Intravenous Iron Supplementation or Doubling Erythropoietin Dose for Patients With Chemotherapy-induced Anaemia Inadequately Responsive to Initial Erythropoietin Treatment Alone Unknown status NCT02731378 Phase 4 Erythropoietins (EPO);Aggressive iron dextran supplementation;Erythropoietins (EPO);Sustained iron dextran supplementation
22 Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial Unknown status NCT03229954 Phase 4 iron isomaltoside (Monofer) intravenous infusion;Ferrous sulfate(Feroba-YOU) per oral
23 The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Unknown status NCT02041299 Phase 4 Deferiprone;Deferoxamine
24 A Multi-Center, Open-Label, Randomized, Parallel Group Study of the Efficacy and Safety of Ferrlecit in the Maintenance of Iron Stores and Serum Hemoglobin Concentration in Hemodialysis Patients Receiving Erythropoietin. Unknown status NCT00223938 Phase 4 Oral Iron;sodium ferric gluconate;sodium ferric gluconate
25 Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia Unknown status NCT01084122 Phase 4 Iron sucrose
26 Predictors of Response to Treatment With Iron and Erythropoietin in Dialysis Anaemia Unknown status NCT02707757 Phase 4 Iron sucrose;Erythopoietin stimulating agent
27 Preoperative, Single-dose Intravenous Iron Formulation to Reduce Post-surgical Complications in Patients Undergoing Major Abdominal Surgery: a Pilot Randomised Control Trial (PIRCAS Trial - Pilot) Unknown status NCT03295851 Phase 4 Ferric carboxymaltose;Ferrous Fumarate
28 Multicenter Randomized Controlled Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion in the Treatment of Preoperative Anaemia in Colorectal Cancer Patients Unknown status NCT02243735 Phase 4 Ferrous fumarate;ferric(III)carboxymaltose
29 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
30 Sienna+® Injection Time Study: A Prospective Multicentre, Controlled Clinical Trial to Evaluate the Performance of Superparamagnetic Iron Oxide vs. Standard Technique as Tracer in Sentinel Node Biopsy Unknown status NCT02612870 Phase 4
31 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
32 The Value of Iron Treatment for Postoperative Patients With Anemia: a Randomized Double Blind Controlled Trial Unknown status NCT01975272 Phase 4 Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
33 Double-Blind, Single-Center Interventional Trial To Evaluate The Effect Of Intravenous Iron Versus Placebo On Cerebral Dopamine Receptor Density In Non Anaemic Premenopausal Women With Low Ferritin Levels And Fatigue Unknown status NCT03305705 Phase 4 Iron Carboxymaltose;Sodium chloride 0.9%
34 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
35 A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance Unknown status NCT00103753 Phase 4 deferiprone
36 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
37 Prevention of Iron Deficiency in Breastfed Infants Completed NCT01444261 Phase 4
38 Periodic Versus Continuous (at Every Session of Hemodialysis) iv Iron Supplementation in Chronic HD Patients Completed NCT02787824 Phase 4 Iron Sucrose Supplement
39 Effectiveness of Adaptation of the Dose of Iron Supplementation in Pregnancy on Maternal-child Health. Randomized Clinical Trial (ECLIPSES) Completed NCT03196882 Phase 4 40mg/day of iron;20mg/day of iron;80mg/day of iron
40 Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile and the Recovery of Hemoglobin in Total Knee and Hip Arthroplasty Surgery? Completed NCT02544464 Phase 4 ferric carboxymaltose 1000 mg;placebo
41 Evaluation of Iron Species in Healthy Subjects Treated With Generic and Reference Sodium Ferric Gluconate Completed NCT02399449 Phase 4 sodium ferric gluconate (brand);sodium ferric gluconate (generic)
42 Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes Completed NCT00470158 Phase 4
43 Doubling the Iron Dose VS Single Dose Iron Supplementation to Prevent Iron Deficiency Anemia (IDA) in Twin Pregnant Women: A Randomized Controlled Trial Completed NCT03836703 Phase 4 Feroglobin single daily use;Feroglobin twice daily dose
44 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
45 Low Dose Intravenous Versus Oral Iron for Iron Deficiency Anemia Starting Late in Pregnancy: A Randomized Controlled Trial Completed NCT00746551 Phase 4 Ferli-6® (Continental Pharm co., ltd.);Venofer® (Vifor AG, St. Gallen, Switzerland)
46 Phase IV Study of Oral Administration of Bovine Lactoferrin (bLf) to Prevent and Cure Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) Until Delivery in Hereditary Thrombophilia (HT) Affected Pregnant Women Completed NCT01221844 Phase 4 FerroGrad by Abbott
47 Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass Completed NCT02271997 Phase 4 Ferrous fumarate;Ferrous gluconate;Iron(III)carboxymaltose
48 Optimizing Early Child Development in the Primary Care Practice Setting: Pragmatic Randomized Trial of Iron Treatment for Young Children With Non-anemic Iron Deficiency (OptEC) Completed NCT01481766 Phase 4
49 Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy: a Randomised, Comparative, Open-label Trial Completed NCT03188445 Phase 4 Iron Isomaltoside 1000;ferrous fumarate with ascorbic acid
50 A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia Completed NCT02905539 Phase 4 Iron Isomaltoside 1000;Ferric Carboxymaltose

Search NIH Clinical Center for Iron Metabolism Disease

Cochrane evidence based reviews: iron metabolism disorders

Genetic Tests for Iron Metabolism Disease

Anatomical Context for Iron Metabolism Disease

MalaCards organs/tissues related to Iron Metabolism Disease:

40
Kidney, Liver, Bone Marrow, Colon, Thyroid, Breast, Small Intestine

Publications for Iron Metabolism Disease

Articles related to Iron Metabolism Disease:

(show top 50) (show all 20244)
# Title Authors PMID Year
1
In vitro bioaccessibility and bioavailability of iron from fenugreek, baobab and moringa. 42 61
32745843 2021
2
Fortified Foods Are Major Contributors to Apparent Intakes of Vitamin A and Iodine, but Not Iron, in Diets of Women of Reproductive Age in 4 African Countries. 42
32534454 2020
3
Net benefit and cost-effectiveness of universal iron-containing multiple micronutrient powders for young children in 78 countries: a microsimulation study. 42
32710863 2020
4
Elevated soluble transferrin receptor levels reflect increased erythropoietic drive rather than iron deficiency in pediatric sickle cell disease. 61 54
20486179 2010
5
Alpha 1-acid glycoprotein, hepcidin, C-reactive protein, and serum ferritin are correlated in anemic schoolchildren with Schistosoma haematobium. 54 61
20410090 2010
6
Posttransplant anemia in solid organ recipients. 54 61
20303457 2010
7
Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency. 54 61
19624802 2010
8
Ceramide in suicidal death of erythrocytes. 54 61
20502001 2010
9
Iron stores, periodic leg movements, and sleepiness in obstructive sleep apnea. 54 61
20465018 2009
10
[Soluble tranferrin receptor in the biological diagnosis of iron deficiency. Report of 24 cases]. 54 61
20209848 2009
11
Ferric carboxymaltose in patients with heart failure and iron deficiency. 61 54
19920054 2009
12
The role of transferrin receptor 1 and 2 in transferrin-bound iron uptake in human hepatoma cells. 54 61
19828835 2009
13
Impact of socioeconomic and health related factors on the iron status of adolescent girls from two boarding schools in Southern Benin. 54 61
20306766 2009
14
[Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)]. 61 54
20232547 2009
15
Transferrin and ferritin response to bacterial infection: the role of the liver and brain in fish. 61 54
19428486 2009
16
Differential ferritin expression is associated with iron deficiency in coeliac disease. 61 54
19404207 2009
17
Influence of inflammation as measured by alpha-1-acid glycoprotein on iron status indicators among HIV-positive postpartum Zimbabwean women. 61 54
18506200 2009
18
Pediatric reference intervals for soluble transferrin receptor and transferrin receptor-ferritin index. 54 61
19718534 2009
19
Evaluation of iron deficiency as a nutritional adaptation to infectious disease: an evolutionary medicine perspective. 54 61
18949769 2009
20
Abnormal brain iron homeostasis in human and animal prion disorders. 61 54
19283067 2009
21
Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. 54 61
19147412 2009
22
Early effects on T lymphocyte response to iron deficiency in mice. Short communication. 61 54
18825318 2009
23
Differing expression of genes involved in non-transferrin iron transport across plasma membrane in various cell types under iron deficiency and excess. 54 61
18830567 2009
24
Suicide for survival--death of infected erythrocytes as a host mechanism to survive malaria. 54 61
19710527 2009
25
Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. 54 61
18987297 2009
26
The soluble transferrin receptor (TfR)-F-Index is not applicable as a test for iron status in patients with chronic lymphocytic leukemia. 61 54
19743956 2009
27
[Immune, inflammatory, and nutritional protein profile in children with iron deficiency in Côte d'Ivoire]. 54 61
19801348 2009
28
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. 54 61
18815282 2009
29
Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. 54 61
18974579 2008
30
Parenteral ascorbic acid in haemodialysis patients. 54 61
18827578 2008
31
Erythrocyte programmed cell death. 54 61
18720418 2008
32
[Old and new iron parameters in iron metabolism and diagnostics]. 61 54
18791966 2008
33
Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. 54 61
18469314 2008
34
Iron-independent phosphorylation of iron regulatory protein 2 regulates ferritin during the cell cycle. 54 61
18574241 2008
35
Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. 54 61
18613854 2008
36
Soluble transferrin receptor and sTfR-F index for assessing concurrent iron deficiency in patients with chronic renal failure. 61 54
18317758 2008
37
Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment. 54 61
18174266 2008
38
[Expression of iron regulatory protein-2 and ferritins in intestinal mucosa of rats with iron deficiency]. 54 61
18549630 2008
39
Reticulocyte haemoglobin content vs. soluble transferrin receptor and ferritin index in iron deficiency anaemia accompanied with inflammation. 54 61
18279424 2008
40
Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. 54 61
18029550 2008
41
Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. 61 54
18201677 2008
42
Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. 54 61
18212498 2008
43
Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. 61 54
18094727 2008
44
Prognostic value of reticulocyte hemoglobin content to diagnose iron deficiency in 6-24-month-old children. 54 61
18971604 2008
45
Effect of erythropoietin on hepcidin, DMT1 with IRE, and hephaestin gene expression in duodenum of rats. 54 61
18306987 2008
46
Potential roles of erythropoietin in the management of anaemia and other complications diabetes. 54 61
17645562 2008
47
The relationship between iron deficiency anemia and lipid metabolism in premenopausal women. 54 61
18004086 2007
48
Molecular genetic studies of DMT1 on 12q in French-Canadian restless legs syndrome patients and families. 54 61
17510944 2007
49
Iron deficiency and NRAMP1 polymorphisms (INT4, D543N and 3'UTR) do not contribute to severity of anaemia in tuberculosis in the Indonesian population. 61 54
17466092 2007
50
Inflammation and iron deficiency in the hypoferremia of obesity. 54 61
17438557 2007

Variations for Iron Metabolism Disease

Expression for Iron Metabolism Disease

Search GEO for disease gene expression data for Iron Metabolism Disease.

Pathways for Iron Metabolism Disease

Pathways related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 TFRC TF SLC40A1 SLC11A2 SLC11A1 HEPH
2 12.37 SLC11A2 IREB2 HBB G6PD CP ACO1
3
Show member pathways
12.06 TFRC TF SLC40A1 SLC11A2 SLC11A1 HEPH
4
Show member pathways
11.7 SLC40A1 SLC11A2 SLC11A1 HEPH CP
5 11.69 TFRC TF EPO
6 11.55 TFRC TF EPO CP
7 11.5 TF SLC40A1 SLC11A2 HEPH FTL CYBRD1
8 11.25 TFRC TF SLC40A1 SLC11A2 FTL CP
9 10.39 HJV HFE HAMP
10 10.3 TFRC TFR2 TF SLC40A1 SLC11A2 IREB2

GO Terms for Iron Metabolism Disease

Cellular components related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 TFRC TF HJV HFE HBB HAMP
2 early endosome GO:0005769 9.71 TFRC TF SLC11A2 HFE
3 endosome membrane GO:0010008 9.67 TFRC TF SLC11A2 SLC11A1
4 blood microparticle GO:0072562 9.56 TFRC TF HBB CP
5 recycling endosome GO:0055037 9.46 TFRC TF SLC11A2 HFE
6 basal part of cell GO:0045178 9.13 TF SLC11A2 HFE
7 HFE-transferrin receptor complex GO:1990712 9.02 TFRC TFR2 TF HJV HFE

Biological processes related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 10.04 TF SLC40A1 SLC11A2 SLC11A1 HFE HEPH
2 iron ion transport GO:0006826 9.81 TFRC TFR2 TF SLC11A2 SLC11A1 IREB2
3 response to ethanol GO:0045471 9.8 MT-CYB HAMP G6PD
4 acute-phase response GO:0006953 9.77 TFR2 HFE HAMP EPO CRP
5 iron ion homeostasis GO:0055072 9.73 TFR2 TF SLC40A1 SLC11A2 SLC11A1 IREB2
6 transferrin transport GO:0033572 9.71 TFRC TFR2 TF HFE
7 osteoclast differentiation GO:0030316 9.69 TFRC TF IREB2
8 copper ion transport GO:0006825 9.65 SLC11A2 HEPH CP
9 response to iron ion GO:0010039 9.65 TFR2 SLC11A2 HFE HAMP CYBRD1
10 response to vitamin A GO:0033189 9.63 HAMP EPO
11 iron ion transmembrane transport GO:0034755 9.63 SLC40A1 SLC11A2 SLC11A1
12 positive regulation of bone resorption GO:0045780 9.62 TFRC TF
13 multicellular organismal iron ion homeostasis GO:0060586 9.62 SLC40A1 SLC11A2 SLC11A1 HAMP
14 response to hyperoxia GO:0055093 9.61 MT-CYB EPO
15 intestinal absorption GO:0050892 9.61 IREB2 ACO1
16 cellular response to iron ion GO:0071281 9.61 TFR2 TF HFE
17 erythrocyte maturation GO:0043249 9.6 G6PD EPO
18 manganese ion transport GO:0006828 9.59 SLC11A2 SLC11A1
19 manganese ion transmembrane transport GO:0071421 9.58 SLC11A2 SLC11A1
20 positive regulation of peptide hormone secretion GO:0090277 9.58 TFR2 HFE
21 cadmium ion transmembrane transport GO:0070574 9.57 SLC11A2 SLC11A1
22 citrate metabolic process GO:0006101 9.56 IREB2 ACO1
23 divalent inorganic cation transport GO:0072511 9.55 SLC40A1 SLC11A2
24 response to iron ion starvation GO:1990641 9.54 HFE HAMP
25 regulation of iron ion transport GO:0034756 9.52 TF HFE
26 cellular iron ion homeostasis GO:0006879 9.5 TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1

Molecular functions related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.95 MT-CYB HEPH G6PD CYBRD1 CP
2 copper ion binding GO:0005507 9.65 HEPH HAMP CP
3 metal ion transmembrane transporter activity GO:0046873 9.56 SLC11A2 SLC11A1
4 co-receptor binding GO:0039706 9.54 TFR2 HFE
5 ferrous iron binding GO:0008198 9.54 TF HEPH FTL
6 ferric iron binding GO:0008199 9.52 TF FTL
7 ferroxidase activity GO:0004322 9.51 HEPH CP
8 manganese ion transmembrane transporter activity GO:0005384 9.49 SLC11A2 SLC11A1
9 ferrous iron transmembrane transporter activity GO:0015093 9.46 SLC40A1 SLC11A2
10 cadmium ion transmembrane transporter activity GO:0015086 9.43 SLC11A2 SLC11A1
11 aconitate hydratase activity GO:0003994 9.4 IREB2 ACO1
12 transition metal ion transmembrane transporter activity GO:0046915 9.32 SLC11A2 SLC11A1
13 iron-responsive element binding GO:0030350 9.26 IREB2 ACO1
14 transferrin receptor activity GO:0004998 9.16 TFRC TFR2
15 transferrin receptor binding GO:1990459 9.13 TF HJV HFE
16 iron ion transmembrane transporter activity GO:0005381 8.8 SLC40A1 SLC11A2 SLC11A1

Sources for Iron Metabolism Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....